Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 17 analysts have evaluated Sage Therapeutics (NASDAQ:SAGE), with a mix of bullish, bearish, and neutral ratings. The average 12-month price target has declined from $25.92 to $19.76. Recent analyst actions include several downgrades and lowered price targets, reflecting cautious sentiment. Sage Therapeutics has shown significant revenue growth but faces challenges with negative net margins and ROA.
May 29, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has received mixed analyst ratings over the past three months, with a notable decline in the average 12-month price target from $25.92 to $19.76. Recent downgrades and lowered price targets by several analysts indicate cautious sentiment towards the stock.
The decline in the average 12-month price target and multiple downgrades by analysts suggest a negative short-term outlook for Sage Therapeutics. The cautious sentiment is likely to put downward pressure on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100